These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 27226828)

  • 21. Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ren S; Squires H; Hock E; Kaltenthaler E; Rawdin A; Alifrangis C
    Pharmacoeconomics; 2019 Sep; 37(9):1073-1080. PubMed ID: 30547369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cost-effectiveness of transcatheter aortic valve implantation versus surgical aortic valve replacement in patients with severe aortic stenosis at high operative risk.
    Fairbairn TA; Meads DM; Hulme C; Mather AN; Plein S; Blackman DJ; Greenwood JP
    Heart; 2013 Jul; 99(13):914-20. PubMed ID: 23696198
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ustekinumab for the treatment of moderate to severe psoriasis.
    Gospodarevskaya E; Picot J; Cooper K; Loveman E; Takeda A
    Health Technol Assess; 2009 Oct; 13 Suppl 3():61-6. PubMed ID: 19846031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available?
    Bullement A; Meng Y; Cooper M; Lee D; Harding TL; O'Regan C; Aguiar-Ibanez R
    J Med Econ; 2019 Mar; 22(3):205-214. PubMed ID: 30422080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association Between the Use of Surrogate Measures in Pivotal Trials and Health Technology Assessment Decisions: A Retrospective Analysis of NICE and CADTH Reviews of Cancer Drugs.
    Pinto A; Naci H; Neez E; Mossialos E
    Value Health; 2020 Mar; 23(3):319-327. PubMed ID: 32197727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ren S; Bermejo I; Simpson E; Wong R; Scott DL; Young A; Stevenson M
    Pharmacoeconomics; 2018 Jul; 36(7):769-778. PubMed ID: 29502174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma : An Evidence Review Group Evaluation of the NICE Single Technology Appraisal.
    Thielen FW; Büyükkaramikli NC; Riemsma R; Fayter D; Armstrong N; Wei CY; Huertas Carrera V; Misso K; Worthy G; Kleijnen J; Corro Ramos I
    Pharmacoeconomics; 2019 Aug; 37(8):975-984. PubMed ID: 30547368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Role of Noncomparative Evidence in Health Technology Assessment Decisions.
    Griffiths EA; Macaulay R; Vadlamudi NK; Uddin J; Samuels ER
    Value Health; 2017 Dec; 20(10):1245-1251. PubMed ID: 29241883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence.
    Bullement A; Taylor M; McMordie ST; Waters E; Hatswell AJ
    Pharmacoeconomics; 2019 Nov; 37(11):1383-1390. PubMed ID: 31250397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Opportunity costs and local health service spending decisions: a qualitative study from Wales.
    Karlsberg Schaffer S; Sussex J; Hughes D; Devlin N
    BMC Health Serv Res; 2016 Mar; 16():103. PubMed ID: 27012523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Uttley L; Whyte S; Gomersall T; Ren S; Wong R; Chambers D; Tappenden P
    Pharmacoeconomics; 2017 Jul; 35(7):717-726. PubMed ID: 27943135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Etelcalcetide for Treating Secondary Hyperparathyroidism: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
    Rose M; Shepherd J; Harris P; Pickett K; Lord J
    Pharmacoeconomics; 2018 Nov; 36(11):1299-1308. PubMed ID: 29691773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
    Jäkel A; Plested M; Dharamshi K; Modha R; Bridge S; Johns A
    Appl Health Econ Health Policy; 2013 Feb; 11(1):27-43. PubMed ID: 23329379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rivaroxaban for Preventing Atherothrombotic Events in People with Acute Coronary Syndrome and Elevated Cardiac Biomarkers: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Pandor A; Pollard D; Chico T; Henderson R; Stevenson M
    Pharmacoeconomics; 2016 May; 34(5):463-77. PubMed ID: 26689783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. "Yes", "No" or "Yes, but"? Multinomial modelling of NICE decision-making.
    Dakin HA; Devlin NJ; Odeyemi IA
    Health Policy; 2006 Aug; 77(3):352-67. PubMed ID: 16213624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dinutuximab Beta for Treating Neuroblastoma: An Evidence Review Group and Decision Support Unit Perspective of a NICE Single Technology Appraisal.
    Pennington B; Ren S; Barton S; Bacelar M; Edwards SJ
    Pharmacoeconomics; 2019 Aug; 37(8):985-993. PubMed ID: 30465228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene.
    Blommestein HM; Armstrong N; Ryder S; Deshpande S; Worthy G; Noake C; Riemsma R; Kleijnen J; Severens JL; Al MJ
    Pharmacoeconomics; 2016 Jan; 34(1):23-31. PubMed ID: 26314282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Clinical and Cost Effectiveness of Ustekinumab for the Treatment of Psoriatic Arthritis: A Critique of the Evidence.
    O'Connor J; Rice S; Smith A; Rodgers M; Lopez RR; Craig D; Woolacott N
    Pharmacoeconomics; 2016 Apr; 34(4):337-48. PubMed ID: 26818809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.